stopping glp 1 side effects Life‐years balance of MBS versus GLP‐1 RA over 10 years (per 100 FDA warns Novo Nordisk of

Positive data readouts from outcome trials, a head start in negotiating access for these drugs with PBMs, and long lead times to ramp up manufacturing all contribute to a very significant competitive moat for both LLY and NVO as the GLP-1 market rapidly grows over the next decade

Injectable GHK-Cu costs slightly more per month but delivers significantly more potent systemic effects

These medications include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 agonist

Dantzer 52 and Gpx4 Tg/+ mice from Q

Tao, Y., Li, M., Ren, J

10.1002/art.42273 150 TanQ.ChenB.WangQ.XuW.WangY.LinZ.et al (2018)